2025-01-01 2025-12-31 2025-12-31 false 09713504 Lifeproven Limited Pending iso4217:GBP xbrli:pure 097135042025-01-01 097135042025-12-31 097135042025-01-01 2025-12-31 09713504bus:SmallEntities2025-01-01 2025-12-31 09713504bus:AuditExempt-NoAccountantsReport2025-01-01 2025-12-31 09713504bus:FullAccounts2025-01-01 2025-12-31 09713504core:WithinOneYear2025-12-31 09713504core:AfterOneYear2025-12-31 09713504core:WithinOneYear2025-01-01 2025-12-31 09713504core:AfterOneYear2025-01-01 2025-12-31 09713504core:CurrentFinancialInstruments2025-12-31 09713504core:Non-currentFinancialInstruments2025-12-31 09713504core:CurrentFinancialInstruments2025-01-01 2025-12-31 09713504core:Non-currentFinancialInstruments2025-01-01 2025-12-31 09713504core:LandBuildings2025-01-01 2025-12-31 09713504core:FurnitureFittings2025-01-01 2025-12-31 09713504core:OfficeEquipment2025-01-01 2025-12-31 09713504core:Vehicles2025-01-01 2025-12-31 09713504core:PlantMachinery2025-01-01 2025-12-31 09713504core:OtherPropertyPlantEquipment2025-01-01 2025-12-31 09713504core:LandBuildings2025-12-31 09713504core:PlantMachinery2025-12-31 09713504core:Vehicles2025-12-31 09713504core:FurnitureFittings2025-12-31 09713504core:OfficeEquipment2025-12-31 09713504core:OtherPropertyPlantEquipment2025-12-31 09713504core:Right-of-useAssets2025-01-01 2025-12-31 09713504core:Right-of-useAssets2025-12-31 09713504core:Goodwill2025-01-01 2025-12-31 09713504core:PatentsTrademarksLicencesConcessionsSimilar2025-01-01 2025-12-31 09713504core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-01 2025-12-31 09713504core:OtherResidualIntangibleAssets2025-01-01 2025-12-31 09713504core:Goodwill2025-12-31 09713504core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-12-31 09713504core:PatentsTrademarksLicencesConcessionsSimilar2025-12-31 09713504core:OtherResidualIntangibleAssets2025-12-31 09713504dpl:CostSales2025-01-01 2025-12-31 09713504dpl:AdministrativeExpenses2025-01-01 2025-12-31 09713504dpl:DistributionCosts2025-01-01 2025-12-3109713504core:ShareCapital2025-12-31 09713504core:SharePremium2025-12-31 09713504core:RevaluationReserve2025-12-31 09713504core:OtherReservesSubtotal2025-12-31 09713504core:ShareCapitalPreferenceShares2025-12-31 09713504core:CapitalRedemptionReserve2025-12-31 09713504core:OtherCapitalReserve2025-12-31 09713504core:RetainedEarningsAccumulatedLosses2025-12-3109713504core:ShareCapital2025-01-01 2025-12-31 09713504core:SharePremium2025-01-01 2025-12-31 09713504core:RevaluationReserve2025-01-01 2025-12-31 09713504core:OtherReservesSubtotal2025-01-01 2025-12-31 09713504core:RetainedEarningsAccumulatedLosses2025-01-01 2025-12-310971350412025-01-01 2025-12-31 0971350422025-01-01 2025-12-3109713504core:ShareCapital12025-01-01 2025-12-31 09713504core:ShareCapital22025-01-01 2025-12-3109713504core:SharePremium12025-01-01 2025-12-31 09713504core:SharePremium22025-01-01 2025-12-3109713504core:RevaluationReserve12025-01-01 2025-12-31 09713504core:RevaluationReserve22025-01-01 2025-12-3109713504core:RetainedEarningsAccumulatedLosses12025-01-01 2025-12-31 09713504core:RetainedEarningsAccumulatedLosses22025-01-01 2025-12-310971350412025-01-01 2025-12-3109713504core:Non-currentFinancialInstrumentscore:CostValuation2025-01-01 09713504core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3109713504core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-01-01 09713504core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-12-31 09713504core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-31 09713504core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-12-3109713504core:Non-currentFinancialInstruments2025-12-31 09713504core:Non-currentFinancialInstruments2024-12-31097135042024-01-01 097135042024-12-31 097135042024-01-01 2024-12-31 09713504core:WithinOneYear2024-12-31 09713504core:AfterOneYear2024-12-31 09713504core:CurrentFinancialInstruments2024-12-31 09713504core:Non-currentFinancialInstruments2024-12-31 09713504core:LandBuildings2024-12-31 09713504core:PlantMachinery2024-12-31 09713504core:Vehicles2024-12-31 09713504core:FurnitureFittings2024-12-31 09713504core:OfficeEquipment2024-12-31 09713504core:OtherPropertyPlantEquipment2024-12-31 09713504core:Right-of-useAssets2024-12-31 09713504core:Goodwill2024-12-31 09713504core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-31 09713504core:PatentsTrademarksLicencesConcessionsSimilar2024-12-31 09713504core:OtherResidualIntangibleAssets2024-12-31 09713504dpl:AdministrativeExpenses2024-01-01 2024-12-3109713504core:ShareCapital2024-12-31 09713504core:SharePremium2024-12-31 09713504core:RevaluationReserve2024-12-31 09713504core:OtherReservesSubtotal2024-12-31 09713504core:ShareCapitalPreferenceShares2024-12-31 09713504core:CapitalRedemptionReserve2024-12-31 09713504core:OtherCapitalReserve2024-12-31 09713504core:RetainedEarningsAccumulatedLosses2024-12-3109713504core:RetainedEarningsAccumulatedLosses2024-01-01 09713504core:ShareCapital2024-01-01 09713504core:SharePremium2024-01-01 09713504core:RevaluationReserve2024-01-01 09713504core:ShareCapital2024-01-01 2024-12-31 09713504core:SharePremium2024-01-01 2024-12-31 09713504core:RevaluationReserve2024-01-01 2024-12-31 09713504core:OtherReservesSubtotal2024-01-01 2024-12-31 09713504core:RetainedEarningsAccumulatedLosses2024-01-01 2024-12-310971350412024-01-01 2024-12-31 0971350422024-01-01 2024-12-3109713504core:ShareCapital12024-01-01 2024-12-31 09713504core:ShareCapital22024-01-01 2024-12-3109713504core:SharePremium12024-01-01 2024-12-31 09713504core:SharePremium22024-01-01 2024-12-3109713504core:RevaluationReserve12024-01-01 2024-12-31 09713504core:RevaluationReserve22024-01-01 2024-12-3109713504core:RetainedEarningsAccumulatedLosses12024-01-01 2024-12-31 09713504core:RetainedEarningsAccumulatedLosses22024-01-01 2024-12-3109713504bus:Director12025-01-01 2025-12-3109713504bus:Director22025-01-01 2025-12-3109713504bus:PrivateLimitedCompanyLtd2025-01-01 2025-12-31
Lifeproven Limited
Unaudited Financial Statements
for the year ended 31 December 2025
Company registration number 09713504
(England and Wales)

Company Information

For the year ended 31 December 2025
Directors Hinds, Adam James
Relfe, Jordan William

Registered office C/O TN6 Ltd
Pine Grove Enterprise Centre
Pine Grove
Crowborough
TN6 1DH

Registered number 09713504

Accountant TN6 Ltd
Pine Grove Enterprise Centre
Pine Grove
CROWBOROUGH
East Sussex
TN6 1DH

Statement of Financial Position

As at 31 December 2025
Notes
2025
2024
£
£
£
£
Fixed assets
Tangible assets
4
407
891
407
891
Current assets
Stocks
5
86,440
184,283
Debtors
6
367,940
419,474
Cash at bank and in hand
131,897
23,511
586,277
627,268
Creditors
Amounts falling due within one year
7
(151,085)
(218,832)
(151,085)
(218,832)
Net current assets (liabilities)
435,192
408,436
Total assets less current liabilities
435,599
409,327
Creditors
Amounts falling due after one year
8
-
(140,327)
-
(140,327)
Net assets (liabilities)
435,599
269,000
Capital and reserves
Called up share capital
9
100
104
Profit and loss account
435,499
268,896
Total equity
435,599
269,000

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 22 June 2026 and are signed on its behalf by:

Hinds, Adam James
Hinds, Adam James
Director
Relfe, Jordan William
Relfe, Jordan William
Director

Company registration number 09713504

Notes to the Financial Statements

For the year ended 31 December 2025

1. Statutory information

The company is a private company and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Foreign currencies

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

2.4. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Office and computer equipment
33
Straight-line

2.5. Stocks and work in progress

Inventories are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, inventories are assessed for impairment. If an item of inventory is impaired, the carrying amount is reduced to its selling price less costs to complete and sell, and the impairment loss is recognised immediately in the income statement. When inventories are sold, the carrying amount is recognised as an expense in the period in which the related revenue is recognised.


For long-term contracts where the company provides services or bespoke goods, work in progress is recognised as a contract asset. These are measured by reference to the stage of completion of the contract activity at the reporting date, based on the progress made towards the complete satisfaction of the performance obligations.

2.6. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.7. Trade and other creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.8. Related parties

A related party is a person or entity that is related to the company. This includes individuals with control or significant influence, members of key management personnel, and entities within the same group. All transactions with related parties are disclosed in the notes to the financial statements. Disclosure includes the nature of the related party relationship, the amount of the transactions, and any outstanding balances and commitments at the reporting date. As permitted by FRS 102, disclosure is not required of transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member.

2.9. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

3. Employees

The average number of employees during the year was 5 (2024: 8).

4. Tangible fixed assets

Office equipment
Total
£
£
Cost
At 1 January 2025
4,506
4,506
Additions
565
565
At 31 December 2025
5,071
5,071
Depreciation and impairment
At 1 January 2025
3,615
3,615
Charge for the period
1,049
1,049
At 31 December 2025
4,664
4,664
Net book value
At 31 December 2025
407
407
At 31 December 2024
891
891

5. Stocks and work in progress

2025
2024
£
£
Work in progress
86,440
184,283
Total
86,440
184,283

6. Debtors

2025
2024
£
£
Trade debtors
181,881
282,452
Amounts owed by associates, joint ventures and participating interests
94,088
59,276
Other debtors
75,786
53,802
Directors loan accounts
16,185
23,944
Total due within one year
367,940
419,474
Total due after one year
-
-
Total
367,940
419,474

7. Creditors due within one year

2025
2024
£
£
Bank loans and overdrafts
-
8,250
Trade creditors
3,417
-
Other creditors
4,046
12,327
Taxation and social security
139,482
194,755
Accruals and deferred income
4,140
3,500
Total
151,085
218,832

8. Creditors due after one year

2025
2024
£
£
Bank loans and overdrafts
-
140,327
Total
-
140,327

9. Share capital

2025
2024
£
£
Allotted, called up and fully paid
Ordinary
100
104
Total
100
104

10. Related party transactions

At the end of the year the company was owed £94,088 (£59,276 - 2024) from it's related parties.


Other Information

The Company has taken advantage of the exemption available in section 33.1A of FRS 102 not to disclose transactions with the ultimate parent company or any wholly owned subsidiary undertaking of the group.

11. Controlling party

Lifeproven Limited is a wholly owned subsidiary of LifeProven Holdings Limited registered in England at Pine Grove Enterprise Centre, Pine Grove, Crowborough, East Sussex TN6 1DH. LifeProven Holdings Limited registered in England is the ultimate parent company.